Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

Sadat City University

Status and phase

Active, not recruiting

Phase 2

Phase 1

Conditions

Fatty Liver, Nonalcoholic

Treatments

Drug: Placebo

Drug: Cilostazol 50 MG

Study type

Interventional

Funder types

Other

Identifiers

NCT04761848

10/2021IRI

Details and patient eligibility

About

The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD. Cilostazol appeared to exert beneficial effects against NAFLD

Enrollment

120 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults between 18 and 60 years of age, both men and women,
Clinical diagnosis of NAFLD, confirmed by imaging exams,
Patients who present levels above the reference values of ALT, AST and ferritin.

Exclusion criteria

Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation.
Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification)
Patients with schistosomiasis;
Hemochromatosis
Wilson's disease
Viral or autoimmune hepatitis
HIV virus carriers
Woman who is breastfeeding
Users of illicit drugs
Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months;
Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months
Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days
Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or -Alzheimer's disease)
Patients who do not participate in all stages of the research.